What Estrella Immunopharma Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 2 | 2 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 2 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Liu Cheng | CEO | Aug 25 | Exercise / conversion · M | +100,000 | $0.82 | +$81.5K | 397,437 |
| Xu Jiandong | Chief Financial Officer | Aug 18 | Exercise / conversion · M | +100,000 | $0.82 | +$81.5K | 365,488 |
| Xu Jiandong | Chief Financial Officer | Oct 07 | Open-market buy · P | +1,000 | $1.33 | +$1.33K | 265,488 |
| Xu Jiandong | Chief Financial Officer | Sep 22 | Open-market buy · P | +1,000 | $1.16 | +$1.16K | 16,700 |
| Xu Jiandong | Chief Financial Officer | Sep 11 | Open-market buy · P | +100 | $1.04 | +$104 | 264,588 |
| Owl Creek Asset Management, L.p. | 10% owner | Sep 29 | Other Transaction · J | −255,000 | $10.86 | −$2.77M | 0 |
| Li Jianwei | Co-Chief Executive Officer | Mar 04 | Open-market buy · P | +141,970 | $314,700.00 | +$44.7B | 1,253,730 |
Loading...
